ストックスクリーナーアプリを入手
12.90
5.49%
-0.75
アフターアワーズ：
12.80
-0.10
-0.78%
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List - GlobeNewswire
Syndax Pharmaceuticals, Inc. (SNDX) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire
Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move? - Simply Wall Street
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - TradingView
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) - PR Newswire
Syndax Pharmaceuticals Suffers Pipeline BlowSyndax Pharmaceuticals (NASDAQ:SNDX) - Benzinga
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $37.27, Implies 125% Upside - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap DownHere's What Happened - MarketBeat
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. - Barron's
Syndax Pharmaceuticals Selloff After IPF Trial Failure Appears 'Overdone,' BofA Securities Says - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed as Buy by HC Wainwright - MarketBeat
BofA Securities Adjusts Syndax Pharmaceuticals PT to $23 From $26, Maintains Buy Rating - Yahoo Finance
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Syndax Pharmaceuticals (NasdaqGS:SNDX) Stock Forecast & Analyst Predictions - Simply Wall Street
Syndax Pharmaceuticals (SNDX) Stock Forecast and Price Target 2026 - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed? - Yahoo Finance
Syndax Pharmaceuticals ends IPF development after Phase 2 axatilimab miss - Mugglehead Investment Magazine
SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Yahoo Finance
Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria - GuruFocus
Syndax Pharmaceuticals' Axatilimab Trial in Pulmonary Fibrosis Misses Primary Endpoint - Yahoo Finance
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development - Yahoo Finance
Syndax Pharmaceuticals stock tumbles on failed IPF trial - Yahoo Finance
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis - GlobeNewswire
Possible Bearish Signals With Syndax Pharmaceuticals Insiders Disposing Stock - Moomoo
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Cross Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Cash flow from investing activities of Syndax Pharmaceuticals Inc – HAN:1T3 - TradingView
Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX) - Seeking Alpha
Syndax Pharmaceuticals poised for growth with p... - Pluang
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors - BioWorld News
Diaceutics (DXRX) Enhances Multi-Year Relay Collaboration with Syndax Pharmaceuticals to Advance Acute Leukaemia Precision Oncology Commercialisation - Kalkine Media
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews
WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily
Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - webull.com
Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6%Here's Why - MarketBeat
Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX? - StockInvest.us
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan
Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others - Value Research
1.60%
0.00%
大文字化:
|
ボリューム (24 時間):